

Seasonal Influenza Vaccines

H. Keipp Talbot, MD, MPH
Chair, Influenza Work Group

Advisory Committee on Immunization Practices

October 28, 2020



Influenza Work Group

ACIP Members

Keipp Talbot (Chair)
Robert Atmar
Kevin Ault
Hank Bernstein
Peter Szilagyi

Ex Officio Members

Michael Cooper (NIH)
Cynthia Nolletti (FDA)
Chris Roberts (NIH)
Susan Wollersheim (FDA)

Liaison Representatives and Consultants

Ed Belongia
Sarah Coles
Buddy Creech
Sarah Despres
Jeff Duchin
Sandra Fryhofer
Robyn Harrison
Denise Jamieson
Wendy Keitel
Marie-Michèle Léger
Jamie Loehr
Susan Lett

Mark Mulligan
Flor Munoz
Kathy Neuzil
William Schaffner
Rob Schechter
Ken Schmader
Patsy Stinchfield
Tamara Sheffield
Chip Walter
Kelsey Young
Matthew Zahn

Recap of Influenza Session, June 2020

- 2019-20 influenza activity, vaccine effectiveness, and safety updates
- Work Group considerations and proposed 2020-21 recommendations

Work Group Activities Since June 2020

- Finalization of publication of the 2020-21 ACIP Influenza statement
 - Published in MMWR August 20, 2020
- Review and discussion of 2019-20 estimates influenza vaccine effectiveness, influenza disease burden, and burden averted through vaccination
- Discussion of data from randomized controlled trial of cell culture-based influenza vaccine, Flucelvax Quadrivalent, among children aged ≥ 2 through < 18 years.

Session Overview

- **Efficacy Results of FLUCELVAX Quadrivalent (cclIV4) in Subjects Aged ≥ 2 to < 18 Years**
 - Dr. Gregg Sylvester, Seqirus
- **Influenza Disease Burden and Vaccine Impact Estimates, 2019-20 Season**
 - Dr. Carrie Reed, CDC/NCIRD
- **End-of-Season Estimates of 2019–20 Seasonal Influenza Vaccine Effectiveness against Medically Attended Influenza from three U.S. Networks**
 - Dr. Lisa Grohskopf, CDC/NCIRD
- **Updates and WG considerations**
 - Dr. Lisa Grohskopf, CDC/NCIRD